Rapid Micro Biosystems, Inc.
RPID
$2.46
$0.187.90%
| Weiss Ratings | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.70 | |||
| Price History | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -9.56% | |||
| 30-Day Total Return | 28.80% | |||
| 60-Day Total Return | 145.93% | |||
| 90-Day Total Return | 127.78% | |||
| Year to Date Total Return | 150.23% | |||
| 1-Year Total Return | 146.59% | |||
| 2-Year Total Return | 112.07% | |||
| 3-Year Total Return | -59.00% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -43.62% | |||
| 52-Week Low % Change | 293.10% | |||
| Price | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.04 | |||
| 52-Week Low Price | $0.58 | |||
| 52-Week Low Price (Date) | Jul 03, 2024 | |||
| 52-Week High Price (Date) | Feb 19, 2025 | |||
| Valuation | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 98.58M | |||
| Enterprise Value | 53.53M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.08 | |||
| Earnings Per Share Growth | -11.74% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.56 | |||
| Price/Book (Q) | 1.30 | |||
| Enterprise Value/Revenue (TTM) | 1.91 | |||
| Price | $2.46 | |||
| Enterprise Value/EBITDA (TTM) | -1.14 | |||
| Enterprise Value/EBIT | -1.07 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 43.77M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 978 349 3200 | |||
| Address | 1001 Pawtucket Boulevard West Lowell, MA 01854 | |||
| Website | www.rapidmicrobio.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -177.95% | |||
| Profit Margin | -167.15% | |||
| Management Effectiveness | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -25.83% | |||
| Return on Equity | -- | |||
| Income Statement | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 28.05M | |||
| Total Revenue (TTM) | 28.05M | |||
| Revenue Per Share | $0.64 | |||
| Gross Profit (TTM) | -109.00K | |||
| EBITDA (TTM) | -46.96M | |||
| EBIT (TTM) | -49.92M | |||
| Net Income (TTM) | -46.89M | |||
| Net Income Avl. to Common (TTM) | -46.89M | |||
| Total Revenue Growth (Q YOY) | 29.68% | |||
| Earnings Growth (Q YOY) | 13.48% | |||
| EPS Diluted (TTM) | -1.08 | |||
| EPS Diluted Growth (Q YOY) | 14.75% | |||
| Balance Sheet | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 51.22M | |||
| Cash Per Share (Q) | $1.17 | |||
| Total Current Assets (Q) | 80.92M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 75.35M | |||
| Current Ratio (Q) | 4.607 | |||
| Book Value Per Share (Q) | $1.75 | |||
| Total Assets (Q) | 98.17M | |||
| Total Current Liabilities (Q) | 17.57M | |||
| Total Debt (Q) | 6.17M | |||
| Total Liabilities (Q) | 22.82M | |||
| Total Common Equity (Q) | 75.35M | |||
| Cash Flow | RPID - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 36.66M | |||
| Cash from Financing (TTM) | 203.00K | |||
| Net Change in Cash (TTM) | -7.29M | |||
| Levered Free Cash Flow (TTM) | -28.83M | |||
| Cash from Operations (TTM) | -44.15M | |||
